Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry
Restricted accessResearch articleFirst published online 2020
Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry
CapodannoDAlfonsoFLevineGN, et al.
ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol2018;
72: 2915–2931.
2.
UrbanPMehranRColleranR, et al.
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J2019;
40: 2632–2653.
3.
SibbingDAradiDAlexopoulosD, et al.
Updated Expert Consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv2019;
12: 1521–1537.
4.
CostaFvan KlaverenDJamesS, et al.
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet2017;
389: 1025–1034.
5.
ValgimigliMBuenoHByrneRA, et al.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2018;
39: 213–260.
6.
NeumannFJSousa-UvaMAhlssonA, et al.
2018 ESC/EACTS Guidelines on myocardial revascularization. Eurointervention2019;
14 :1435–1534.
7.
MehranRRaoSVBhattDL, et al.
Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation2011;
123: 2736–2747.
IwanagaYMiyazakiS.Heart failure, chronic kidney disease, and biomarkers: An integrated viewpoint. Circ J2010;
74: 1274–1282.
10.
KwokCSMartinezSCPancholyS, et al.
Effect of comorbidity on unplanned readmissions after percutaneous coronary intervention (from the Nationwide Readmission Database). Sci Rep2018;
8: 11156.
11.
D’AscenzoFBertainaMFioravantiF, et al.
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. Eur J Prev Cardiol2020;
27: 696–705.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
